



CALL FOR LETTERS OF INTENT 2020 Pediatrics Supplement

The LOI submission deadline has been extended to August 6th, 2018

We are pleased to announce plans for a special journal supplement in Pediatrics, currently under preparation with leadership from the Autism Intervention Research Network on Physical Health (AIR-P) and the Autism Speaks Autism Treatment Network (AS ATN). The timeline for publication will likely be spring 2020.

Editorial Team

We are thrilled to announce our editorial team for our 2020 special supplement to Pediatrics:

Dr. Evdokia Anagnostou, Dr. Susan Levy, Dr. Micah Mazurek, and Dr. Jeremy Veenstra-VanderWeele

Evdokia Anagnostou, MD, is a child neurologist and senior clinician scientist at Holland Bloorview Kids Rehabilitation Hospital. She is also associate professor in the Department of Pediatrics at the University of Toronto and Assistant Director of Holland Bloorview's Research Institute. Dr. Anagnostou also serves as the co-lead of the Autism Research Centre (ARC). She holds a Canada Research Chair in translational therapeutics in Autism Spectrum Disorder (ASD) and the Dr. Stuart D. Sims Chair in Autism at Holland Bloorview. Dr. Anagnostou's research focuses on translating genomic and systems biology findings into novel treatments for ASD.

Susan E. Levy, MD, MPH is board certified in Neurodevelopmental Disabilities. She is a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania (UPENN), a member of the Division of Developmental and Behavioral Pediatrics (DBP), the Institutional Review Board of The Children's Hospital of Philadelphia (CHOP), and the Center for Public Health Initiatives (CPHI) at UPENN. Her clinical activities include attending physician in outpatient clinics in DBP and Founder and Director of the Regional Autism Clinic at CHOP. Dr. Levy is active in policy and advocacy on a local, regional and national level. She is chair of the Autism Subcommittee for the Council on Children with Disabilities of the AAP. She is active in research activities as a member of the Center for Autism Research (CAR) of the Children's Hospital of Philadelphia. Her research interests include early identification of children with autism spectrum disorder (ASD), epidemiology of ASD and Complementary and Alternative Medical treatments of ASD.

Micah Mazurek, PhD, is a clinical psychologist and Associate Professor at the University of Virginia where she directs the Supporting Transformative Autism Research (STAR) initiative. Prior to her current position, she was an Associate Professor at the University of Missouri and at the Thompson Center for Autism and Neurodevelopmental Disorders and served as Director of the Missouri Leadership Education in Neurodevelopmental Disabilities (LEND) program and Co-PI of the Missouri Autism Treatment Network (ATN) site. Dr. Mazurek has clinical expertise in assessment and treatment of autism and other neurodevelopmental disorders and has an active program of federally-funded research focused on understanding and improving

outcomes in autism. Her current research focuses on developing new tools, techniques, and technologies for improving diagnosis, treatment, and access to care for individuals with autism and their families. Dr. Mazurek has been actively involved in the ATN for a number of years, including leading and collaborating on a number of ATN/AIR-P research studies, serving as the Research Representative on the ATN/AIR-P Steering Executive Committee, and serving as Co-Chair of the ATN Behavior Science and Sleep Committees.

Jeremy Veenstra-VanderWeele, MD, is a child and adolescent psychiatrist who uses molecular and translational neuroscience tools in the pursuit of new treatments for autism spectrum disorder and pediatric obsessive-compulsive disorder. His molecular laboratory focuses on genetic mouse models with abnormal social or compulsive-like behavior. His translational research program at the Center for Autism and the Developing Brain studies potential treatments for autism spectrum disorder and related genetic syndromes. Dr. Veenstra-VanderWeele trained with Edwin H. Cook, M.D., at the University of Chicago and Randy Blakely, Ph.D., at Vanderbilt University. He moved from Vanderbilt to Columbia University in 2014 and became the Ruane Professor and Division Director of Child and Adolescent Psychiatry in 2017. Dr. Veenstra-VanderWeele serves as an Associate Editor of *Autism Research*, the *Journal of the International Society for Autism Research*, and of the *Journal of Autism and Developmental Disorders*. He also co-chairs the Autism and Intellectual Disability Committee of the *American Academy of Child and Adolescent Psychiatry*. He sits on the Scientific Advisory Boards of the *Brain and Behavior Research Foundation* and *Autism Speaks*. His work has garnered multiple awards, including the Blanche Ittelson Award for Research in Child and Adolescent Psychiatry from the *American Psychiatric Association*.

Supplement Content

We are pleased to welcome and review LOIs that could arise from or include: a) an overview of the AIR-P network, b) evidence-based guidelines, c) research studies arising from Registry analyses, d) a report from the AIR-B guidelines project, e) reports from AIR-P clinical research studies, f) work stemming from autism learning network initiatives, and g) reports from selected R40 or other Autism CARES Act intervention research projects funded by HRSA.

Intended Recipients of this Call

Through this call, we invite all interested members of the AIR-P/ATN Network to provide and submit a Letter of Intent (LOI) for manuscripts to be considered for publication in the planned 2020 Pediatrics supplement. There is no commitment to publish until final reviews are complete. If you are planning on submitting a manuscript to a different journal before the supplement publication date, you are welcome to submit an LOI and can withdraw before the list of included manuscripts is finalized.

PLEASE NOTE: If you currently have a manuscript being reviewed elsewhere but want it to be considered for this supplement as well, you are welcome to respond to this call for LOIs.

LOI Requirements

LOIs should not exceed 2 pages. The LOI should be single-side, single-spaced in Times New Roman, 12-point font. All LOI submissions are required to include the following:

- Manuscript title
- Author name(s)
- Abstract (background, research questions, method, preliminary results, conclusions)
- Summary of possible results and implications
- Description of available data
- **Identify Reviewers & Conflicts:**
 - Provide the name and contact information for 2 individuals to serve as potential reviewers for your planned manuscript. Suggested individuals should have no conflicts of interest, and should not have any knowledge of the planned manuscript.
 - Provide the name of any individual(s) who may have a conflict so that we don't invite the individual(s) to review the manuscript.

LOI Submission * **Extended Deadline** *

LOIs must be received, via email, by 5pm ET on Monday, August 6th, 2018. Please submit your LOI as a single Word document to the Network Clinical Coordinating Center, Megan Eaves (meaves@mgh.harvard.edu).

For questions related to LOI submission, please contact:

Megan Eaves, Clinical Research Coordinator

E-mail: meaves@mgh.harvard.edu

Phone: 617-724-8546

Manuscript Submission and Timeline

Manuscript submissions are due by 5pm ET on Friday, November 2nd, 2018. Please carefully review the accompanying timeline and manuscript requirements distributed with this LOI release.

The LOI submission deadline is August 6th, 2018
The manuscript submission deadline is November 30th, 2018

This special supplement is supported by a cooperative agreement UA3 MC11054 through the U.S. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Program to the Massachusetts General Hospital. This work is conducted through the Autism Speaks Autism Treatment Network serving as the Autism Intervention Research Network on Physical Health.